Kommentar zu: ProstataCa – Extraprostatische Ausdehnung als Risikofaktor erst ab ISUP Grad 2

• Literatur

• 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe AWMF): S3-Leitlinie Prostatakarzinom, Version 7.0 – Mai 2024, AWMF-Registernummer: 043–022OL.
• 2 Carlsson S, Benfante N, Alvim R. et al. Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. The Journal of Urology 2020; 203: 1122-1127
• 3 Rezaee ME, Pallauf M, Fletcher SA. et al. Risk of Biochemical Recurrence in Patients With Grade Group 1 Prostate Cancer With Extraprostatic Extension Treated With Radical Prostatectomy. The Journal of Urology 2024; 211: 407-414
• 4 Eggener SE, Berlin A, Vickers AJ. et al. Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2022; 40: 3110-3114
• 5 Ferro M, Lucarelli G, de Cobelli O. et al. The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. Minerva urology and nephrology 2021; 73: 442-451